Trials / Recruiting
RecruitingNCT07308782
A Phase Ⅱa Clinical Study of CL-197 Capsules
An Exploratory Pharmacodynamic Clinical Study of CL-197 Capsules in Treatment Naive Patients With Human Immunodeficiency Virus (HIV-1)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Henan Genuine Biotech Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the antiretroviral activity, safety and pharmacokinetics of single dose of CL-197 capsule in three dose groups administered to antiretroviral treatment-naïve adult participants with human immunodeficiency virus type 1 (HIV-1) infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CL-197 capsules | Participants will take a single dose of CL-197 capsules at a dose of 10 mg, 30 mg or 60 mg, orally on an empty stomach. |
Timeline
- Start date
- 2025-11-29
- Primary completion
- 2026-12-01
- Completion
- 2027-03-01
- First posted
- 2025-12-30
- Last updated
- 2026-01-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07308782. Inclusion in this directory is not an endorsement.